Pfizer (PFE)

Executive Summary

Pfizer Inc. (NYSE: PFE) is a global biopharmaceutical leader with a market cap of ~$156B, spanning small molecules, vaccines, biologics, and RNA/gene therapy. The company has over 175 years of innovation, 90+ commercial products, and 102 FDA approvals. Despite a strong legacy, Pfizer faces headwinds from declining COVID-19 product sales (Comirnaty and Paxlovid) and upcoming patent expiries on key assets like Xeljanz and Eliquis (the latter is partnered with BMS). To counter this, Pfizer is executing a pipeline-driven turnaround focused on oncology (e.g., Vepdegestrant for breast cancer, ADC candidates), rare disease (gene therapies for hemophilia and DMD), and vaccines (RSV, pneumococcal 20-valent). Recent acquisitions like Seagen (targeting cancer ADCs) and Biohaven (CGRP for migraine) bolster the mid- to late-stage pipeline. The company also prioritizes cost-cutting measures, aiming for $4B in annual savings by 2026. With a P/E ratio near historical lows and a dividend yield above 5%, Pfizer offers value for patient investors, though near-term revenue declines and lack of blockbuster replacements remain risks. The conviction score reflects a balanced risk/reward: a strong pipeline and cost discipline offset by revenue uncertainty.

Upcoming Catalysts (preview)

• H2 2026FDA decision on Vepdegestrant (PF-0686572) for ER+/HER2- metastatic breast cancer (Phase 3 TACTiK-003 data)75% success
• Q1 2027Phase 3 readout for PF-06939926 (gene therapy) in Duchenne muscular dystrophy50% success
• Q3 2026RSV vaccine (Abrysvo) label expansion to younger adults and immunocompromised populations60% success